SecBot SecBot
6-K ·Filed Sep 14, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001575872-26-000646
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the company's response to the USFDA and any subsequent regulatory action (e.g., warning letter, import alert) that could affect API supply or revenue from the Mexico facility. The two observations are not detailed, so the risk is currently low but warrants tracking for escalation.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$11.91
T+0 close · Sep 14, 2026 · via day close
Latest settled
−3.02%
T+1 · $11.55
Vs SPY
−2.56%
α at T+1
Next horizon
T+5
due 8w ago
  1. T+0 · Sep 14 $11.91entry
  2. T+1 · 2mo ago −3.02%α −2.56% · $11.55
  3. T+5 · due 8w ago Pending
  4. T+20 · due 5w ago Pending
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepec, Morelos) between July 17 and September 8, 2026, issuing a Form FDA 2953 with two observations. The company will respond within the stipulated timeline. This is a routine regulatory follow-up with no material financial impact disclosed, and the two observations are not quantified or characterized as critical.

Key Facts

  • USFDA conducted a records assessment under Section 704(a)(4) at Dr. Reddy's API facility in Mexico (Industrias Químicas Falcón de México, S.A. de C.V.) from July 17 to September 8, 2026.
  • The USFDA issued a Form FDA 2953 containing two observations; the company will respond within the stipulated timeline.
  • No warning letter, shutdown, import alert, or material financial impact was disclosed in the filing.

Financial Impact

No financial figures disclosed; two observations from a records assessment with no indication of material cost or revenue impact.

Risk Factors

  • Potential escalation to a warning letter or import alert if the USFDA deems the response inadequate, which could disrupt API production and sales.
  • Uncertainty around the nature of the two observations, if they relate to data integrity or quality systems, remediation costs could be material.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
31% bullish (45 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000646
Document: 0001575872-26-000646-index.html0001575872-26-000646
Document: 0001575872-26-000646.txt0001575872-26-000646

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026